key: cord-0900981-j6zfrecf
authors: Boon, Siaw Shi; Xia, Chichao; Wang, Maggie Haitian; Yip, Ka Lai; Luk, Ho Yin; Li, Sile; Ng, Rita W. Y.; Lai, Christopher K. C.; Chan, Paul Kay Sheung; Chen, Zigui
title: Temporal-Geographical Dispersion of SARS-CoV-2 Spike Glycoprotein Variant Lineages and Their Functional Prediction Using in Silico Approach
date: 2021-10-26
journal: mBio
DOI: 10.1128/mbio.02687-21
sha: 9ac64afbc8a8596659342d3da945b3e99a7b928e
doc_id: 900981
cord_uid: j6zfrecf

SARS-CoV-2 is a positive-sense single-stranded RNA virus with emerging mutations, especially on the Spike glycoprotein (S protein). To delineate the genomic diversity in association with geographic dispersion of SARS-CoV-2 variant lineages, we collected 939,591 complete S protein sequences deposited in the Global Initiative on Sharing All Influenza Data (GISAID) from December 2019 to April 2021. An exponential emergence of S protein variants was observed since October 2020 when the four major variants of concern (VOCs), namely, alpha (α) (B.1.1.7), beta (β) (B.1.351), gamma (γ) (P.1), and delta (δ) (B.1.617), started to circulate in various communities. We found that residues 452, 477, 484, and 501, the 4 key amino acids located in the hACE2 binding domain of S protein, were under positive selection. Through in silico protein structure prediction and immunoinformatics tools, we discovered D614G is the key determinant to S protein conformational change, while variations of N439K, T478I, E484K, and N501Y in S1-RBD also had an impact on S protein binding affinity to hACE2 and antigenicity. Finally, we predicted that the yet-to-be-identified hypothetical N439S, T478S, and N501K mutations could confer an even greater binding affinity to hACE2 and evade host immune surveillance more efficiently than the respective native variants. This study documented the evolution of SARS-CoV-2 S protein over the first 16 months of the pandemic and identified several key amino acid changes that are predicted to confer a substantial impact on transmission and immunological recognition. These findings convey crucial information to sequence-based surveillance programs and the design of next-generation vaccines.

Global dispersion of SARS-CoV-2. Up to 30 April 2021, more than 150 million confirmed cases were recorded worldwide (Fig. 1A) . The global spread of SARS-CoV-2 was first recognized in March 2020. Another wave further attacked Europe and North America beginning October 2020, while the proportion of cases increased again in Asia and South America from early 2021 (Fig. 1B) . By the end of April 2021, nearly 1.3 million SARS-CoV-2 complete genomes were characterized (Fig. 1C) . Compared to the prototype (NC_045512, 614D), numerous nonsynonymous mutations accumulated across the viral genome, with 97.3% of SARS-CoV-2 sequences containing S-D614G in the S protein (Fig. 1D ). Among them, 4 S-D614G variants of concern (VOCs), namely, a (B.1.1.7), b (B.1.351), g (P.1), and d (B.1.617), emerging with multiple additional amino acid changes in the S1-RBD, have caused community outbreaks since the end of 2020 in different countries (Fig. 1E) .

Genomic diversity of SARS-CoV-2 S protein. Based on the amino acid sequence alignment of S protein, at least 14,479 unique variants that formed 1,257 Pangolin lineages (defined by Global Initiative on Sharing All Influenza Data [GISAID]) were clustered, with amino acid mutation sites ranging between 1 and 16 (including indel events). Before WHO declared the COVID-19 outbreak a pandemic (December 2019 to February 2020), the S gene was relatively conserved, and 75% (52/69) of unique variants belonged to the prototype (614D) ( Fig. 2A) , which corresponded to one or two amino acid changes ( (Fig. 3A) . However, it is worth noting that the lower level of mutation identified in the early stage of prepandemic could be due to the limited availability of virus sequences (see the bar chart in Fig. 2A) .

The temporal dispersion and reported signature amino acid mutations of the four VOC lineages are described below.

(i) Alpha lineage, a (B.1.1.7). The a (B.1.1.7) variant lineage was first recorded in a patient from the United Kingdom in September 2020 (EPI_ISL_601443) (Fig. 3B ). Soon after, this variant lineage was found in India in early October 2020 and then in the United States in early November 2020. By the end of April 2021, at least 472,406 a (B.1.1.7) complete genomes were reported from 122 countries/regions across all six continents, with a dramatic increase from December 2020 (3% of total genomes) to April 2021 (76%). Countries like the United Kingdom (N = 217,819, 56% of the total sequenced genomes), the United States (70,810, 19%), Germany (46,497, 61%) , Sweden (19,126, 63%) , and France (14, 721 , 54%) provided the largest number of sequenced genomes. At least 3,776 S protein variants belonging to a (B.1.1.7) variant lineage were identified, in which all contain 2 deletion events (amino acids 69 to 70 and 144) and 7 mutations (N501Y, A570D, D614G, P681H, T716I, S982A, and D1118H) ( Fig. 3A ; see also Fig. S1 in the supplemental material). In addition, L5F, L18F, S98F, and K1191N were found in 2.6%, 1.2%, 1.3%, and 2.6% of a (B.1.1.7) S variant sequences, respectively. When aligning the a (B.1.1.7) whole genomes against the prototype, at least 10 conserved amino acid variations within ORF1a (T1001I, A1708D, I2230T), ORF1b (P214L), ORF8 (R52I, Y73C), and N gene (D3L, R203K, G204R, S235F) were observed (Fig. S1 ).

(ii) Beta lineage, b (B.1.351). The b (B.1.351) variant was first reported from South Africa in October 2020 (EPI_ISL_712081) (Fig. 3C) . One month later, it was detected in Bangladesh, Switzerland, and several African countries. Up to April 2021, the b (B.1.351) variant lineage was widely found in many parts of Europe, Asia and North America, with a total of 12,832 sequences reported. Of these, 18% were from South Africa, followed by France (11%), Germany (10%), the United States (8%), Belgium (6%), and other 78 countries/regions across all 6 continents. A total of 139 unique S protein variants of b (B.1.351) were clustered, with the majority carrying 7 consensus amino acid variations (D80A, D215G, K417N, E484K, N501Y, D614G, and A701V) and 1 deletion (amino acid 242) (Fig. 3A, Fig. S2 ). Fifty-four percent of sequenced b (B.1.351) S genes also contained an L18F mutation. Other than the S protein, the majority of b (B.1.351) genomes had amino acid changes within ORF1a (T265I, K1655N, K3353R), ORF1b (P214L), ORF3a (Q57H, S171L), E (P71L), and N (T205I) (Fig. S2) .

(iii) Gamma lineage, c (P.1). In early November 2020, Brazil reported a new SARS-CoV-2 variant designated g (P.1) (EPI_ISL_718682) (Fig. 3D ). This variant lineage spread outside South America in early January 2021, and as of April 2021, the United States (N = 3,972), Brazil (N = 1,580), Italy (N = 631), Belgium (N = 499), the Netherlands (N = 224), and the other 36 countries/regions worldwide have sequenced at least 8,005 g (P.1) complete genomes, revealing 153 S protein variants. Twelve signature amino acid mutations (L18F, T20N, P26S, D138Y, R190S, K417T, E484K, N501Y, D614G, H655Y,  T1027I , and V1176F) were observed in the S protein as well as other consensus changes, including ORF1a (S1188L and K1795Q), ORF1b (P214L and E1164D), ORF3a (S253P), ORF8 (E92K), and N (P80R, R203K, and G204R), across the whole genome (Fig. S3) .

(iv) Delta lineage, d (B.1.617). In early 2021, India faced a new wave of the pandemic. A novel variant lineage was detected within the local community that could be traced back as early as the beginning of October 2020 (EPI_ISL_1415203) (Fig. 3E ). This lineage was characterized with a signature mutation, L452R, within S1-RBD. Natural selection of S gene variations. When the S protein variants (N = 3,242, each represented by at least 11 reported identical sequences) were aligned, at least 693 amino acid variations (including indels) were observed (Fig. 4) . Likelihood ratio tests for natural selection showed that at least 51 amino acids in the S protein were under positive selection, including 20 and 5 sites located in the S1-NTD (aa 13 to 305) and the S1-RBD (319 to 541) regions, respectively (Table 1) . Among them, 4 amino acid mutations within the S1-RBD (aa 452, 477, 484 and 501) might have an impact on the binding affinity to hACE2. L452R was highly specific to d (B. In silico structure prediction of S protein variants and classification. The cryogenic electron microscopy (cyro-EM) structures of S protein for the prototype and a (B.1.1.7) and b (B.1.351) variants are available in the Protein Data Bank (PDB) (27, 32, 33) . Utilizing SWISS-MODEL protein homology modeling (34), we predicted structures of .200 variants of interest that were represented by at least 500 different S protein sequences to assess their structural characteristics with reference to the prototype. As S protein is a homotrimeric protein, we superposed monomer using SWISS-MODEL with the closed conformation of S protein (prototype) (PDB entry 6ZGI), generating a predicted structure that was 92% identical to the known structure (Fig. S5 ). We then superposed the predicted S protein structure of a monomutant containing a D614G mutation. Dual mutants containing D614G and other amino acid changes, including those under positive selection or observed in VOCs (L5F, L18F, S98F, W152L/C, E154K, L222V, and A262S in S1-NTD; N439K, L452Q/R, S477N, L478R/K, E484K/Q, N501Y, and A570D within S1-RBD; Q677H/P and P681H/R in S1-CTD; T716I, S982A, and D1118H in S2) as well as commonly deleted residues (aa 69 to 70, 144, and 241 to 243) were further simulated for structure prediction. From our prediction models, none of the Table 1 ). Other amino acid changes are visualized in gray. The dotted lines in red show S1-NTD and S1-RBM regions of SARS-CoV-2 S gene, of which our amino acid sites that bind to hACE2 were under positive selection (452, 477, 484, and 501). The maximum likelihood tree on the left was constructed using RAxML based on the concatenated nucleotide sequence alignments of 12 open reading frames (ORFs). The phylogenetic positions of the four VOCs (a, b, g, and d ) are highlighted in dark red. The numbers of sequenced isolates (in log 10 ) and amino acid sites of each S gene variant are shown on the right. Mutations observed in at least 50% of sequenced genomes are in italic and bold type.

c Containing at least 100 sequenced genomes, except for the four VOCs.

Boon et al.

® monomutants and deletion mutants affected the S protein structure (.93% identity to the prototype). However, the S-D614G mutation reduced protein structure identity to the prototype by half (51%), altering its S1-RBD conformation primarily (Fig. 5A) . When incorporating D614G in monomutants, we were intrigued to find that mutation of T478I 1 D614G or E484K 1 D614G resulted in mutants with protein structure like the S-D614G mutant, while other amino acid changes at the same residues, such as T478R/ K 1 D614G or E484Q 1 D614G, were similar to the prototype (Fig. 5B ). Next, we predicted the S protein structure of native variants, including the four VOCs (a, b, g, and d ), using the same approach. Based on our prediction models, we categorized the variants into 4 groups (Fig. 6A) , including group 1 of .92% identity to the prototype (Fig. 6Bi) , group 2 of S1-NTD unaligned (Fig. 6Bii) , group 3 of S1-NTD and S1-RBD unaligned (Fig. 6Biii) , and group 4 of S1-RBD unaligned (Fig. 6Biv) . S protein that did not carry D614G mutation was categorized into group 1, while the b (B.1.351) variant that carried additional L18F mutation showed both its S1-NTD and S1-RBD unaligned to the prototype (group 3). As expected, the majority of VOCs carrying mutations within the S1-RBD belonged to group 4.

Impact of amino acid variations in S protein to hACE2 binding and its antigenicity. We next utilized in silico approaches to assess the impact of S protein conformation divergence on their functions, particularly their hACE2 binding affinity and antigenicity.

(i) hACE2 binding affinity. We predicted the binding affinity of S protein variants to hACE2 using pyDock (35) . Our results showed that the binding energy of hACE2 with the prototype (NC_045512) and S-D614G mutant was 245.88 kcal/mol and 247.06 kcal/mol, respectively, while all the variants in groups 1 to 4 bound stronger to hACE2 than the prototype. Notably, the S protein binding affinity of the b (B. (Fig. 6A ). In addition, our results showed that b (B.1.351) and a (B.1.1.7) variants bound stronger than S-D614G to hACE2, which is consistent with previous reports based on both in silico and in vitro studies (36, 37) .

(ii) Antigenicity of S protein variants. As S protein is known to elicit host immune response, we used immunoinformatics tools to predict the antigenicity of the S protein prototype and variants. We used Immune Epitope Database (IEDB) analysis resources to predict the ability of S protein sampled by MHC class I molecules to be presented as antigens. BepiPrep-2.0 (38) was used to predict the probability of S protein being recognized by B cells to produce S-specific immunoglobulins. Our results showed that S protein variants in groups 1, 2, 3, and a (B.1.1.7) in group 4 had a greater, while b (B.1.351), g (P.1), and d (B.1.617) variants in group 4 had a lower, T cell immunogenicity than the prototype (Fig. 6A ). For B cell epitope probability, S proteins featured in groups 1, 2, and 3 scored higher, except for the B.1 variant lineage (EPI_ISL_984896, group 2), which scored similar or higher than the prototype and D614G mutant. S proteins featured in group 4 had a lower B cell epitope probability than the prototype and D614G mutant. These findings indicated that mutation harbored within the VOCs conferred a lower T and B cell immunogenicity of S proteins, allowing the virus to circumvent host immune surveillance.

Prediction on potential amino acid alterations that confer lower immunogenicity. As SARS-CoV-2 continues to mutate, we attempted to predict amino acid mutations that could emerge in SARS-CoV-2 variants. Based on dN/dS ratio and key amino acids involved in immune evasion, we focused on L5, L18, S98, and A222 (S1-NTD), N439, L452, S477, E484, and N501 (S1-RBD), and Q677 and P681 (S1-CTD). We changed each of the nucleotides corresponding to these genetic codes and predicted the potential amino acid mutation that could arise, as shown in Table 1 and Table S1 . Subsequently, using the prototype as a template (NC_045512), we artificially replaced the respective native S protein variants with the predicted amino acids. As D614G mutation achieved a stable mutation, we incorporated the artificial and D614G mutations and analyzed the impact of these amino acid changes to (i) S protein structure and (ii) T and B cell antigenicity. The protein model of SARS-CoV-2 S protein prototype (NC_045512 in blue) was generated using SWISS-MODEL. The monomer of S protein contains S1 and S2 subunits, with the S1 domain further classified into N-terminal domain (S1-NTD), receptor binding domain (S1-RBD), C-terminal domain (S1-CTD) (colored magenta), and S2 domain. The protease cleavage site is located between S1 and S2. When superposing protein models of S-D614G mutant (mutated amino acid residue 614, indicated by a black arrow) onto the prototype, the aligned regions of the two models are indicated in light gray, while the regions where these two proteins are not aligning are indicated in blue (prototype) and red (S-D614G mutant). Note the D614G mutant is 50.53% identical to the prototype. (B) Protein models of S protein containing T478I/R/K or E484K/Q mutations together with D614G double mutations were superposed onto the prototype. The position of the respective amino acid residues mutated is indicated by black arrows. Note the T478R/K 1 D614G and E484Q 1 D614G double mutants are .93% identitical to the prototype, while the S1-RBD domain of T478I 1 D614G and E484K 1 D614G double mutants were not aligned with the prototype.

(i) Impact of artificial amino acid change on S protein structure. Our S protein structure models revealed that all artificial D614G dual mutations containing amino acid changes in S1-NTD, S1-RBD, S1-CTD, or S2 shared a structure that resembled the S-D614G mutant. As mentioned, an exception was observed with T478R/K 1 D614G or E484Q 1 D614G, in which these mutants resembled the prototype (Fig. 5B) .

(ii) Prediction of artificial amino acid change to T and B cell recognition. The prototype had an overall T cell immunogenicity and B cell epitope probability score of 0.436 and 0.470, respectively, while the overall T and B cell immunogenicity scores of the D614G mutant were 0.387 and 0.470, respectively. Among the amino acid mutations found in circulating SARS-CoV-2 variants, E484Q/K, P681H/R/L/S, P936Y/N/H, D950H/A/N, and D1118H/Y had a lower T cell immunogenicity than the prototype and S-D614G mutant (Table S1 ). Among the artificial mutations, A222P/S, N439S, L452P, T478P/S/N, E484L/A/G/V/D, N501S/K, Q677K, P681A/T, T716S/P/K, P936Q, D950Y/Q, and D1118Q resulted in S protein variants with a lower T cell immunogenicity than the prototype and D614G mutant ( Table 2) .

To understand the likeliness of artificial amino acid in altering B cell epitope probability, we assessed the effect of amino acid alterations on the overall B cell epitope probability of the entire S protein. S1 that contained L5V/H/P/R, L18V/I/H/R/P, S98/A/P/ Y/C, A222P/T/S/G/D, K417E/Q/R/G/M, N439Y/I/S/T, T478A/S, E484G/V/D, N501I/E/D/K, T716S/P/A/R/K, D936R/A/Q, and D950R/Y/V/G/Q, S982T/P/L, and D1118R/G/A/Q artificial mutations resulted in S proteins with a lower B cell recognition ability than the respective native amino acids ( Table 2, Table S1 ). Altogether, our findings indicate that mutations on A222, N439, L452, T478, E484, N501, Q677, T716, D936, D950, and D1118 impact virus T and B cell immunogenicity. Notably, we predicted that the presence of N493S, T478S, E484D, N501K, T716K, and D950Q mutations in SARS-CoV-2 variants could confer lower immunogenicity than the native variants. the S prototype. S protein in group 1 did not carry the D614G mutation, while S protein of groups 2, 3, and 4 contained D614G mutation. Also shown are the percent identities of S protein variants to the prototype, predicted binding energy to human angiotensin-converting enzyme 2 (hACE2), major histocompatibility complex class I T cell immunogenicity, and B cell epitope probability of the respective SARS-CoV-2 S protein variant lineages. (B) Protein models of SARS-CoV-2 variants superposed onto the prototype (NC_045512). These proteins were classified into (i) group 1, with the protein sharing .92% structure similarity to the prototype; (ii) group 2, with the S1-NTD of variants unaligned to the prototype; (iii) group 3, with the whole S1 region of S protein variants unaligned to the prototype; and (iv) group 4, with S1-RBD unaligned to the prototype.

Predict the impact of artificial amino acid mutations on S protein functions of SARS-CoV-2 variants. We assessed the impact of artificial mutations on S protein functions of the 4 VOCs (a, b, g, and d ) . We focused on artificial mutations in S1-RBD (N439S, L452P, S477G, T478S, E484D, and N501K) that resulted in S protein conferring a lower antigenicity (Table 2 ) and predicted their protein conformation, hACE2 binding affinity, and antigenicity. These results were summarized in Table 3 .

(i) S protein conformation. We superposed S protein models of a (B. 1.1.7) , b (B.1.351), g (P.1), and d (B.1.617) containing artificial amino acid mutations against the prototype and S-D614G mutant. In general, there was no change in the conformation of S proteins, except for b (B.1.351) variants represented by EPI_ISL_700450 (group 3) and EPI_ISL_712079 (group 4) (Fig. 6A and B) . Strikingly, when N439S or T478S was simulated, or E484K mutation was replaced with E484D in the amino acid sequence of EPI_ISL_700450, its S protein structure featured in group 3 switched to group 4 (Table 3) . On the contrary, adding N439S and L452P or mutations into the existing EPI_ISL_712079 S protein led to a switch of structure featured in group 4 to group 3 (Table S2) .

(ii) hACE2 binding affinity. Artificially mutated S proteins of the SARS-CoV-2 variant lineages displayed a different impact on hACE2 binding affinity. For example, insertion of N439S, L452P, T478S, E484D, or N501K mutations into the existing a (B.1.1.7) S protein conferred a higher binding affinity to hACE2. Similarly, S proteins of b (B.1.351) variants with N439S or T478S insertion, or alteration of N501K to N501Y, resulted in a higher binding affinity to hACE2. Meanwhile, incorporation of N439S artificial mutation into the existing mutations of g (P.1) and d (B.1.617) also resulted in increased binding affinity to hACE2 than their respective natural mutants.

(iii) T and B cell antigenicity. Since the artificial mutations cluster within the S1-RBD, we further examined the B cell epitope probability of the S1-RBD among the variants. The presence of N439S, T478S, and N501K artificial mutations in all four VOCs led to a lower T cell immunogenicity than the respective natural variants. On the other hand, the presence of S477G in a (B.1.1.7), N439S, T478S, and N501K in b (B.1.351), T478S, E484D, and N501K in g (P.1), and E484D in d (B.1.617) resulted in S protein variants with a lower B cell epitope probability.

Collectively, our prediction models indicate that three yet-to-be-identified hypothetical mutations (N439S, T478S, and N501K) alter S protein structure coupled with increased binding affinity to hACE2 and lower immunogenicity. These mutations may confer additional adaptive and survival benefits to the current circulating SARS-CoV-2 variants.

With the ramping up in sequencing capacity and interest, an enormous number of novel variants of SARS-CoV-2 were identified. Mutation occurs partly due to natural selection (39) , and the mutation rate reflects a response to the selection (40) . The mutation rate of SARS-CoV-2 is higher than that of the mild beta-CoVs, such as hCoV-OC43 (8), but lower than that of RNA viruses in general (41) .

In this study, we focused on mutations in the S protein, particularly the key amino acids under positive selection pressure. After stringent filtering, we identified 693 amino acid variations in S protein. Among these amino acid mutations, S-D614G is the mutation that emerged in January 2020 (20, 23) that allows SARS-CoV-2 to bind to cell receptors, predominantly hACE2, and enter host cells more easily (25) . Since the pandemic was declared, strict travel restrictions have been imposed in most countries. Despite this, S-D614G continued to be detected in different countries, indicating that SARS-CoV-2 S-D614G mutant was the parental virus seeding across continents and then continued to mutate independently, giving rise to SARS-CoV-2 variants containing additional signature amino acid mutations.

The amino acid mutation may confer protein structural and functional alteration. The structural change may depend upon the change in the group of charge, polarity, and hydrophobicity of the amino acid and whether or not the amino acid alteration occurs within the functional domain of the protein. For S protein, our prediction models and others (28) showed that single-amino-acid mutation alone can alter the conformation of S1-RBD. Amino acid change of T478I (polar to nonpolar residue) and E484K (negative-to positive-charge residue) did not contribute to the major shift of the S-D614G structure. However, T478R/K (polar to positive-charge residue) and E484Q (negative to polar residue) resulted in a shift of S-D614G to a structure resembling that of the prototype, while amino acid change can lead to a change in S protein antigenicity and binding affinity to hACE2. Of note, the nonsynonymous substitution of frequently mutated amino acids influences S protein conformation. For instance, the B.1.351 variants with an additional L18F mutation resulted in altered S1-NTD and S1-RBD conformation with increased binding affinity to hACE2.

N501Y has also been shown to confer increased infectivity. Even though both the B.1.1.7 and B.1.351 variants harbor the N501Y mutation, they display a different degree of infectivity and antibody neutralization ability. The B.1.351 variant possesses greater infectivity and better resistance to antibody neutralization (42) . In addition, other amino acids are also important to viral pathogenicity. SARS-CoV-2 K417T/E484K dual mutants resist postvaccination serum neutralization to an extent similar to that of the B.1.351 variant (42) , while N439K mutation arose independently in different countries, facilitating viral attachment to hACE2 and resistance to antibody neutralization (43) . Aside from the known mutations, we predicted that if SARS-CoV-2 acquires N439S, T478S, or N501K mutations, the virus will attain a chance to infect host cells even more efficiently and with reduced antigenicity.

Mutation via amino acid deletion may affect virus fitness and is known to influence a wide variety of biological phenomena. However, this may depend on whether the deletion occurs in the vicinity of a functional domain. From our predictive models, deletion of amino acids 69 to 70 and 144, which are signatures of B.1.1.7 variants, may enhance the infectivity of the virus; however, this may not affect its immunogenicity, while deletion of amino acids 241 to 243, located relatively closer to S1-RBD, found in B.1.351, renders lower immunogenicity and higher binding affinity to hACE2.

However, there are several shortfalls of our in silico prediction models. First, S protein models were generated based on the protein structure deposited in the PDB, and amino acid mutations predicted have not been reported before. The precise protein structure of novel mutants might be inaccurate. Second, the docking model utilized a rigid protein structure to predict binding energy, which differs from the natural status of activated S protein when encountering hACE2 or antagonist antibodies (44) . Finally, despite the immunoinformatics tools being useful to predict the antigenic epitope of a protein, they are far from perfect. Therefore, laboratory evidence is paramount to further elucidate the functionality and antigenicity of S protein variants. Nonetheless, our findings provided a foundation to further investigate how SARS-CoV-2 exhibits its infectivity and pathogenicity. Despite these deficiencies, our findings are impactful for preparing the potential threat posed by novel S protein mutations in relation to viral pathogenicity. More importantly, our data are of great importance particularly for vaccine development and anti-SARS-CoV-2 drug discovery.

Metadata and sequence collection. We retrieved 1,294,693 high-quality SARS-CoV-2 complete genome sequences deposited in the GISAID database, with metadata available from 24 December 2019 to 30 April 2021. Among these, 939,591 amino acid sequences encoding the complete S protein were extracted and clustered into 34,134 unique variants using cd-hit (-G 1 -aL 0.0 -c 1 -M 0 -T 0 -d 0 -g 1 -sc 0) (45) . For each variant, the isolate with the earliest collection date was selected as the representative sequence. After removing singletons (N = 19,655), 14,479 variants represented by at least 2 identical S amino acid sequences were retained for further analyses.

Phylogenetic analysis. To assess the evolutionary relationship of the major circulating SARS-CoV-2 variant lineages, the concatenated 12 gene (1a, 1b, S, 3a, E, M, 6, 7a, 7b, 8, N, and 10) nucleotide sequences inferred from the S protein variants (N = 3,242) were aligned using MAFFT v7.402 (46) . The maximal likelihood (ML) tree based on these aligned genomes was constructed using RAxML MPI v8.2.12 (47) with optimized parameters via CIPRES Science Gateway (48) .

Detection of positive selection. Four algorithms within the HyPhy distribution (49) , including FEL (fixed-effects likelihood), FUBAR (fast, unconstrained Bayesian approximation), MEME (mixed-effects model of evolution), and SLAC (single-likelihood ancestor counting), were used to detect the sites under positive selection. An ML tree inferred from 3,242 S gene variant complete genome nucleotide sequences was preconstructed as the phylogenetic input. A codon site with a dN/dS (v ) value of .1 was regarded as under positive selection when the posterior probabilities inferred from the four algorithms were $0.95 (P # 0.05).

Homology modeling of protein structure, structure comparison, and function prediction. S protein structures were predicted using the SWISS-MODEL (34), an automated homology modeling approach, based on SARS-CoV-2 S variant amino acid sequences available in the Protein Data Bank (PDB) (PDB entries 6ZP2, 6VXX, 7LSS, 7LYQ, 7CWN, 7CN8, and 6LXT). Molecular docking of SARS-CoV-2 S proteins and hACE2 (residues 23 to 63) was performed using pyDock (35) and Chimera UCSF (50) . The percent identity of S protein variants and prototype was analyzed using Chimera UCSF. The total binding energy of S proteins to hACE2 was predicted using pyDock. Prediction on major histocompatibility complex (MHC) class I T cell immunogenicity was performed using IEDB analysis resources (51, 52) , while B cell epitope probability of the S1-RBD or entire S protein was predicted using BepiPrep-2.0 (38) .

Data availability. The complete genome sequences of coronaviruses analyzed in this study were downloaded from the Global Initiative on Sharing All Influenza Data (GISAID).

Supplemental material is available online only. 

6 Prediction of S protein structure, binding to hACE2 and antigenicity of SARS-CoV-2 variant lineages. (A) Homology modeling of S proteins of SARS-CoV-2 lineages was performed using SWISS-MODEL

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China

Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding

On the origin and evolution of SARS-CoV-2

The coronavirus proofreading exoribonuclease mediates extensive viral recombination

Recombination, reservoirs, and the modular Spike: mechanisms of coronavirus cross-species transmission

Molecular evolution of human coronavirus genomes

Complete genomic sequence of human coronavirus OC43: molecular clock analysis suggests a relatively recent zoonotic coronavirus transmission event

The origin and underlying driving forces of the SARS-CoV-2 outbreak

Evolutionary history, potential intermediate animal host, and cross-species analyses of SARS-CoV-2

One year of SARS-CoV-2 evolution

Genetic variants of SARS-CoV-2-what do they mean?

Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein

Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19

Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor

Prevalent, protective, and convergent IgG recognition of SARS-CoV-2 non-RBD spike epitopes

Fusion mechanism of 2019-nCoV and fusion inhibitors targeting HR1 domain in spike protein

Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation

Du Plessis L, Pybus OG. 2020. A dynamic nomenclature proposal for SARS

lineages to assist genomic epidemiology

Genomic and evolutionary comparison between SARS-CoV-2 and other human coronaviruses

SARS-CoV-2 D614G variant exhibits efficient replication ex vivo and transmission in vivo

Evaluating the effects of SARS-CoV-2 Spike mutation D614G on transmissibility and pathogenicity

Tracking changes in SARS-CoV-2 Spike: evidence that D614G increases infectivity of the COVID-19 virus

SARS-CoV-2 spike-protein D614G mutation increases virion spike density and infectivity

SARS-CoV-2 viral spike G614 mutation exhibits higher case fatality rate

Spike mutation D614G alters SARS-CoV-2 fitness

Structural impact on SARS-CoV-2 spike protein by D614G substitution

Structural and functional analysis of the D614G SARS-CoV-2 Spike protein variant

The SARS-CoV-2 Spike variant D614G favors an open conformational state

The impact of mutations in SARS-CoV-2 spike on viral infectivity and antigenicity

Escape from neutralizing antibodies 1 by SARS-CoV-2 spike protein variants

Structural basis for enhanced infectivity and immune evasion of SARS-CoV-2 variants

SARS-CoV-2 and bat RaTG13 spike glycoprotein structures inform on virus evolution and furin cleavage effects

SWISS-MODEL: homology modelling of protein structures and complexes

pyDock: electrostatics and desolvation for effective scoring of rigid-body protein-protein docking

Higher infectivity of the SARS-CoV-2 new variants is associated with K417N/T, E484K, and N501Y mutants: an insight from structural data

SARS-CoV-2 B.1.1.7 and B.1.351 spike variants bind human ACE2 with increased affinity

BepiPred-2.0: improving sequence-based B-cell epitope prediction using conformational epitopes

Does mutation rate depend on itself

Why are RNA virus mutation rates so damn high?

Low genetic diversity may be an Achilles heel of SARS-CoV-2

SARS-CoV-2 spike variants exhibit differential infectivity and neutralization resistance to convalescent or post-vaccination sera

COVID-19 Genomics UK (COG-UK) Consortium, et al. 2021. Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunity

Real-time conformational dynamics of SARS-CoV-2 Spikes on virus particles

CD-HIT: accelerated for clustering the next-generation sequencing data

Parallelization of the MAFFT multiple sequence alignment program

RAxML-VI-HPC: maximum likelihood-based phylogenetic analyses with thousands of taxa and mixed models

Creating the CIPRES Science Gateway for inference of large phylogenetic trees

FUBAR: a fast, unconstrained Bayesian AppRoximation for inferring selection

UCSF Chimera: a visualization system for exploratory research and analysis

Improved method for predicting linear B-cell epitopes

Properties of MHC class I presented peptides that enhance immunogenicity

We gratefully acknowledge the authors and originating and submitting laboratories of the sequences from GISAID's EpiFlu Database (https://www.epicov.org/), on which this research is based.Maggie H. Wang is one of the shareholders of Beth Bioinformatics Co. Ltd. All other authors declare no conflict of interest.